

Grifols names Dr. Jörg Schüttrumpf Chief Scientific Innovation Officer

- *Dr. Schüttrumpf will focus on accelerating innovation across the Grifols Group, including continuing projects at Biotest AG*
- *He will lead the development of Grifols' robust innovation pipeline and foster the application of emerging technologies*

Barcelona, Spain, Sept. 4, 2023 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global leader in plasma medicines with more than 110 years contributing to improve the health and well-being of people, today announced that it has appointed Dr. Jörg Schüttrumpf Chief Scientific Innovation Officer (CSIO).

As the head of innovation for the entire Grifols Group, Dr. Schüttrumpf will concentrate on accelerating the development of differentiated plasma and non-plasma medicines in key therapeutic areas, building on Grifols' solid innovation pipeline. His scope includes the entire development cycle for new therapies, from discovery to clinical trial programs, as well as the strategic partnerships and advanced technologies – such as artificial intelligence – needed to achieve the company's innovation goals.

Since early 2022 Dr. Schüttrumpf has been Chief Scientific Officer of Biotest AG, where he had been Head of Global Research since 2012 and Head of Research and Development since 2015. Under his scientific leadership the Biotest team developed therapeutics from human plasma as well as recombinant proteins such as monoclonal antibodies. His recent development focus included three innovative plasma proteins. Yimmugo®, a modern version of an immunoglobulin G preparation with a high-yield process and optimized safety features, was approved last year. The other two plasma therapies are fibrinogen and trimodulin. Both have great therapeutic potential and are successfully developed in phase 3 clinical trials.

Dr. Schüttrumpf is a physician scientist specializing in Transfusion Medicine and Hemostaseology with degrees from Goethe University Frankfurt, Albert-Ludwigs-University Freiburg, and IMD Business School. During his career he worked in leading research institutions both in Germany and in the United States.

“Grifols is extremely pleased to have an experienced, accomplished scientist like Jörg as our CSIO to take Grifols innovation to the next level to benefit patients and all stakeholders,” said Victor Grifols Deu, Grifols Chief Operating Officer. “We've collaborated with Jörg for more than a year now and look forward to having his knowledge, talent and energy at work for all of Grifols.”

In recent years, Grifols has invested in its innovation infrastructure and today has more than 1,200 research staff working together across four global hubs committed to developing potential new therapeutics. In 2021, the company established the Grifols Scientific Innovation Office to unify the company's research and development efforts under one umbrella, ensuring project prioritization and

GRIFOLS

global collaboration across teams. Grifols has recently established important technology partnerships, such as with Google Cloud, to enhance the use of data and new technologies for the benefit of patients.

“Grifols is a leader in the plasma and biotherapeutics industry saving the lives of thousands of patients with its products every day,” said Dr. Schüttrumpf. “I am excited to be part of the Grifols team and I am very grateful about the opportunity to lead its development and innovation initiatives into the future.”

MEDIA CONTACTS:

Grifols Press Office

media@grifols.com

Tel. +34 93 571 00 02

Spain

Duomo Comunicación

Tel.: +34 91 311 92 89 – 91 311 92 90

Raquel Lumbreras

raquel_lumbreras@duomocomunicacion.com

Tel.: +34 659 57 21 85

Borja Gómez

borja_gomez@duomocomunicacion.com

Tel.: 650 40 22 25

Investor contact:

Investor Relations

inversores@grifols.com - investors@grifols.com

Tel.: +34 93 571 02 21

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and our ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with over 390 across North America, Europe, Africa and the Middle East and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. We provide high-quality biological supplies for life-science research, clinical trials, and for manufacturing

GRIFOLS

pharmaceutical and diagnostic products. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 24,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and ethical leadership.

In 2022, Grifols' economic impact in its core countries of operation was EUR 9.6 billion. The company also generated 193,000 jobs, including indirect and induced.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information, please visit [grifols.com](https://www.grifols.com)

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are "future projections and assumptions". Words and expressions such as "believe", "hope", "anticipate", "predict", "expect", "intend", "should", "will seek to achieve", "it is estimated", "future" and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.